Table 1.
Demographic and exposure history of adults receiving yellow fever (YF) vaccination, by YF immunoglobulin M (IgM) status at 3–4 years postvaccination*
| YF IgM positive (N = 29) | YF IgM negative (N = 11) | |||
|---|---|---|---|---|
| No. | (%) | No. | (%) | |
| Female | 14 | (48) | 8 | (73) |
| Age group at follow-up (years) | ||||
| 20–29 | 10 | (34) | 6 | (55) |
| 30–39 | 15 | (52) | 3 | (27) |
| 40–49 | 4 | (14) | 2 | (18) |
| ≥ 50 | 0 | (0) | 0 | (0) |
| Self-reported medical conditions at follow-up | ||||
| Autoimmune disease | 1 | (3) | 1 | (9) |
| Hypertension | 2 | (7) | 0 | (0) |
| Dyslipidemia | 1 | (3) | 0 | (0) |
| Hypothyroidism | 0 | (0) | 1 | (9) |
| Lot of YF vaccine received | ||||
| Lot 1 | 27 | (93) | 10 | (91) |
| Lot 2 | 2 | (7) | 1 | (9) |
| Immune globulin coadministeredwith vaccine | 15 | (52) | 6 | (55) |
| Postvaccination exposures | ||||
| Travel to YF endemic country | 5 | (17) | 4 | (36) |
| Travel to dengue endemic country | 16 | (55) | 9 | (82) |
| Japanese encephalitis vaccine | 2 | (7) | 0 | (0) |
| Tick-borne encephalitis vaccine | 0 | (0) | 0 | (0) |
*
Univariate analysis revealed no significant differences (P < 0.05) between the YF IgM positive and negative groups.